<div id="readability-page-1"><p>H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Cabaletta Bio today and set a price target of $16.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>According to TipRanks, Tsao is a 5-star analyst with an average return of <span>22.0%</span> and a 53.85% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Hansa Biopharma AB, and Alkermes.</p> <p>Cabaletta Bio has an analyst consensus of Strong Buy, with a price target consensus of $18.40.</p></div>

CABA

<p>H.C. Wainwright analyst Douglas Tsao has reiterated a Buy rating on Cabaletta Bio (CABA) with a price target of $16.00. Tsao, a 5-star analyst, has an average return of 22.0% and a success rate of 53.85%. The analyst consensus for Cabaletta Bio is a Strong Buy, with a price target consensus of $18.40.</p>

Cabaletta Bio (CABA) Gets a Buy from H.C. Wainwright